Which of the following is an approved initial pharmacologic option for a moderately agitated patient with IMC-RASS +3 or +4?

• A. Diphenhydramine 50 mg IM/IV/IO
• B. MIDAZOLAM 2.5-5 mg IN/IM/IV/IO; may repeat x1 after 5 min at 2.5 mg
• C. Ketamine 3-4 mg IM
• D. Atropine 1 mg IV

Answer: (B)

When a patient is moderately agitated (RASS +3 to +4), the goal is to calm them quickly in a controllable way to protect both patient and staff while keeping the airway and breathing stable. A benzodiazepine such as midazolam fits this need well because it acts rapidly and can be given through several routes, including intranasal, which is useful when IV access isn’t readily available. The dosing is designed for titration: an initial 2.5–5 mg can be administered by IN/IM/IV/IO, with a possible repeat dose after about 5 minutes at 2.5 mg if agitation persists. This allows you to achieve the desired sedative effect without overshooting, and the dose can be adjusted depending on response.

Diphenhydramine has sedative effects but is slower to take effect and can produce unpredictable sedation and anticholinergic side effects, making it a less reliable first option for rapid, controlled agitation management. Ketamine can provide very rapid sedation but carries risks such as airway management challenges, emergence reactions, and hemodynamic effects, so it’s typically reserved for specific situations or after benzodiazepines have been considered or tried. Atropine is not used to sedate or calm agitation; it’s for other indications like bradycardia or certain poisonings.

So, the approved initial choice for a moderately agitated patient is midazolam with the described dosing and titration plan, reflecting its rapid, controllable onset and flexible routes.